3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Head & Neck
8
Thoracic
2
Dermatologic
2
Breast
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
6
Melanoma
4
Prostatic Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Kidney Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Upper Tract Urothelial Carcinoma
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
pembrolizumab
20
atezolizumab
8
Nivolumab
8
Docetaxel
7
Carboplatin
6
cemiplimab
5
Immune Checkpoint Inhibitors
5
Radiotherapy
4
Paclitaxel
4
Filgrastim
4
Drug Therapy
4
fludarabine
3
durvalumab
3
Radiosurgery
3
Pemetrexed
3
Gemcitabine
3
Fluorouracil
3
Cyclophosphamide
3
Cisplatin
3
Cetuximab
3
Bortezomib
3
niraparib
2
motexafin gadolinium
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
aldesleukin
2
Tobacco Use Cessation Devices
2
Tetrahydrouridine
2
Taxes
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Immunotherapy
×
Genitourinary
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled